DATI PERSONALI

Mattia Barbot

POSIZIONE

MD, PhD, RTdB convenzionato presso U.O.C. Endocrinologia, Azienda Ospedale Università Padova

ESPERIENZE LAVORATIVE

28/03/2024-ongoing — RTdB presso Dipartimento di Medicina-DIMED, Università degli studi di Padova in convezione con SSN in servizio presso UOC di Endocrinologia, Azienda Ospedale Università di Padova

01/04/2021-27/03/2024 — RTdA presso Dipartimento di Medicina-DIMED, Università degli studi di Padova in convezione con SSN in servizio presso UOC di Endocrinologia, Azienda Ospedale Università di Padova

12/2020-03/2021 — Specialista ambulatoriale ULSS2-Marca trevigiana, 24 ore settimanali

2017-2020 — Dottorando di ricerca

Università di Padova, Dipartimento di Medicina (DIMED)

Dottorando di ricerca in Scienze Cliniche e Sperimentali, curriculum Metodologia clinica e medicina dell'esercizio. Scienze endocrinologiche, diabetologiche e nefrologiche. Tutor Prof. Carla Scaroni
Attività assistenziale presso UOC Endocrinologia Azienda Ospedale Università Padova

01/10/2017-31/12/2017 — Incarico libero professionale come specialista Endocrinologo presso U.O.C. Endocrinologia di Padova

07/2011-06/2012 — Servizio di continuità assistenziale ex ASS 6 Friuli Occidentale (8 turni mensili)

Campi di interesse : Patologia ipofisaria e surrenalica

EDUCATION AND TRAINING

1999-2004 — Liceo Scientifico Leopardi-Majorana, diplomato nel 2004 (100/100)

2004-2010 — Facoltà di Medicina e Chirurgia, Università degli Studi di Padova

2008-2009 — Programma Erasmus presso Universidad del Pais Vasco-Euskal Herriko Unibertsitatea, Spain

2009-2012 — Allievo interno presso U.O.C. Endocrinologia, ambulatorio di patologia ipofisaria, tutor prof.ssa Scaroni

14/10/2010 — Laurea in Medicina e Chirurgia, Università degli Studi di Padova (110/110 cum laude)

Novembre 2011 — Training in Good Clinical Practice (GCP)

2011-2012 — Attività di continuità assistenziale presso ex ULSS 106, Pordenone, FVG con 8 turni mensili

2013 — Corso post-specialistico SIE, Parma

Dal 2011 ha frequentato numerosi Congressi Nazionali ed Internazionali con presentazione di abstract nell'ambito della patologia ipofisaria

© European Union, 2002-2013 | http://europass.cedefop.europa.eu

28/07/2017

Specializzazione in Endocrinologia e Malattie del Metabolismo (110/110 cum laude) con tesi dal titolo: *Usefulness of the thromboembolic risk prediction model "CS-VTE score" in patients with Cushing's syndrome: a multicenter Italian retrospective analysis in a large cohort of patients*

07/01/2018-30/06/2018

Soggiorno di ricerca presso IMIBIC (Maimónides Biomedical Research Institute of Córdoba) -Università di Cordoba, Spagna; supervisori prof Justo P. Castaño-Raul Luque; progetto di ricerca incentrato sul ruolo del recettore AVPR1b nella patogenesi della malattia di Cushing

01/10/2017-17/05/2021

Dottoraro in Scienze Cliniche e Sperimentali presso Università degli Studi di Padova, tesi dal titolo: “Recurrent Cushing’s disease after transsphenoidal surgery: predictors, molecular basis and clinical management “

Competenze personali

Madre lingua: Italiano

Altre lingue

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione orale	Produzione orale	
Spagnolo	C2	C2	C2	C2	C1
	Spagnolo				
Inglese	C1	C1	B2	B2	C1
	Inglese				

Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze professionali

Capacità di gestire pazienti ambulatoriali con ogni genere di patologia endocrinologica (tiroidea, paratiroidea, NETs, metabolismo fosfo-calcico, endocrinologia ginecologica, diabete), con particolare competenza nel campo delle patologie ipofisarie e dell’asse ipofisi-surrene. Ottima esperienza nell’esecuzione di ecografie del collo e nella gestione del paziente internistico ricoverato.
Esperienza nella stesura di PDTA aziendali per la gestione del paziente ipofisario

,

Capacità di comunicazione

Buone capacità communicative ed interrelazionali con colleghi e pazienti

Competenze informatiche

Buon utilizzo del pacchetto Microsoft Office™

Buona conoscenza del software statistico SPSS

Patente

B

Elenco pubblicazioni (in grassetto le pubblicazioni:

1. Scaroni C, **Barbot M** (2017) *Sindrome di Cushing e coagulopatie*. L'endocrinologo
2. Ceccato F, Lizzul L, Zilio M, **Barbot M**, Denaro L, Emanuelli E, Alessio L, Rolma G, Manara R, Saller A, Boscaro M, Scaroni C (2016) Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. Horm Metab Res.
3. **Barbot M**, Trementino L, Zilio M, Ceccato F, Albiger N, Daniele A, Frigo AC, Mardari R, Rolma G, Boscaro M, Arnaldi G, Scaroni C (2016) Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. Pituitary.
4. Ceccato F, **Barbot M**, Albiger N, Zilio M, De Toni P, Luisetto G, Zaninotto M, Greggio NA, Boscaro M, Scaroni C, Camozzi V (2016) Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. 175(2):101-6. doi: 10.1530/EJE-16-0104.
5. Ceccato F, **Barbot M**, Zilio M, Frigo AC, Albiger N, Camozzi V, Antonelli G, Plebani M, Mantero F, Boscaro M, Scaroni C (2015) *Screening tests for Cushing's syndrome: urinary free cortisol role measured by LC-MS/MS.* J Clin Endocrinol Metab.
6. Ceccato F, **Barbot M**, Zilio M, Ferasin S, De Lazzari P, Lizzul L, Boscaro M, Scaroni C (2015) *Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample.* Hormones (Athens).
7. Zilio M, Mazzai L, Sartori MT, **Barbot M**, Ceccato F, Daidone V, Casonato A, Saggiorato G, Noventa F, Trementino L, Prandoni P, Boscaro M, Arnaldi G, Scaroni C (2015) *A venous thromboembolism risk assessment model for patients with Cushing's syndrome*. Endocrine
8. Albiger NM, Ceccato F, Zilio M, **Barbot M**, Occhi G, Rizzati S, Fassina A, Mantero F, Boscaro M, Iacobone M, Scaroni C (2015) *An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience*. Clin Endocrinol.
9. Ceccato F, **Barbot M**, Zilio M, Albiger N, Mantero F, Scaroni C.*Therapeutic strategies for Cushing's syndrome: an update.* Expert opinion on Orphanet Drugs 2015. DOI:10.1517/21678707.2015.991714
10. Trementino L, Zilio M, Marcelli G, Michetti G, **Barbot M**, Ceccato F, Boscaro M, Scaroni C, Arnaldi G. *The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study*. Endocrine. 2014 Dec 11.
11. **Barbot M**, Daidone V, Zilio M, Albiger N, Mazzai L, Sartori MT, Frigo AC, Scanarini M, Denaro L, Boscaro M, Casonato S, Ceccato F, Scaroni C (2015) *Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?* Pituitary
12. Ceccato F, Antonelli G, **Barbot M**, Zilio M, Mazzai L, Gatti R, Zaninotto M, Mantero F, Boscaro M, Plebani M, Scaroni C (2014) *The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice*. Eur J Endocrinol.
13. Zilio M, **Barbot M**, Ceccato F, Camozzi V, Bilora F, Casonato A, Frigo AC, Albiger N, Daidone V, Mazzai L, Mantero F, Scaroni C (2014) *Diagnosis and complications of Cushing's disease: gender-related differences*. Clin Endocrinol.
14. Ceccato F, **Barbot M**, Zilio M, Ferasin S, Occhi G, Daniele A, Mazzocut S, Iacobone M, Betterle C, Mantero F, Scaroni C (2013) *Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency*. Eur J Endocrinol.
15. Koutroumpi S, Spiezia L, Albiger N, **Barbot M**, Bon M, Maggiolo S, Gavasso S, Simioni P, Frigo A, Mantero F, Scaroni C (2014) *Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?* Pituitary.
16. **Barbot M**, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, Mantero F, Scaroni C (2014) *Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?* Pituitary.
17. **Barbot M**, Albiger N, Koutroumpi S, Ceccato F, Frigo AC, Manara R, Fassina A, Gardiman MP, Scanarini M, Mantero F, Scaroni C (2013) *Predicting late recurrence in surgically treated patients with Cushing's disease*. Clin Endocrinol.
18. Ceccato F, Trementino L, **Barbot M**, Antonelli G, Plebani M, Denaro L, Regazzo D, Rea F, Frigo AC, Concettoni C, Boscaro M, Arnaldi G, Scaroni C. *Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH dependent Cushing's syndrome*. Clin Endocrinol (Oxf). 2017 Jun 7. doi: 10.1111/cen.13391.
19. Ceccato F, Boccato M, Zilio M, **Barbot M**, Frigo AC, Luisetto G, Boscaro M, Scaroni C, Camozzi V. Body (2017) *Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study*. Horm Metab Res.

19. Ceccato F, Selmin E, Sabbadin C, Dalla Costa M, Antonelli G, Plebani M, **Barbot M**, Betterle C, Boscaro M, Scaroni C. Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr Connect. 2018 Sep 1;7(9):965-974. doi:
20. Ceccato F, Zilio M, **Barbot M**, Albiger N, Antonelli G, Plebani M, Watutantrige-Fernando S, Sabbadin C, Boscaro M, Scaroni C. *Metyrapone treatment in Cushing's syndrome: a real-life study*. Endocrine. 2018 Jul 16.
21. **Barbot M**, Guarnotta V, Zilio M, Ceccato F, Ciresi A, Daniele A, Pizzolanti G, Campello E, Frigo AC, Giordano C, Scaroni C. *Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease*. Endocrine. 2018 Oct;62(1):207-214.
22. **Barbot M**, Ceccato F, Scaroni C. *Diabetes Mellitus Secondary to Cushing's Disease*. Front Endocrinol (Lausanne). 2018
23. Ceccato F, Regazzo D, Barbot M, Denaro L, Emanuelli E, Borsetto D, Rolma G, Alessio L, Gardiman MP, Lombardi G, Albiger N, D'Avella D, Scaroni C. *Early recognition of aggressive pituitary adenomas: a single-centre experience*. Acta Neurochir (Wien). 2018 Jan
24. **Barbot M**, Ceccato F, Zilio M, Albiger N, Sigon R, Rolma G, Boscaro M, Scaroni C, Bilora F. *Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus*. Pituitary. 2018 Feb;21(1):50-55.
25. Ceccato F, **Barbot M**, Albiger N, Antonelli G, Zilio M, Todeschini M, Regazzo D, Plebani M, Lacognata C, Iacobone M, Mantero F, Boscaro M, Scaroni C. *Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma*. Endocrine. 2018 Mar;59(3):510-519.
26. Ceccato F, **Barbot M**, Lizzul L, Selmin E, Saller A, Albiger N, Betterle C, Boscaro M, Scaroni C. *Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study*. Clin Endocrinol (Oxf). 2018 Feb;88(2):201-208.
27. Puglisi S, Perotti P, **Barbot M**, Cosio P, Scaroni C, Stigliano A, Lardo P, Morelli V, Polledri E, Chiodini I, Reimondo G, Pia A, Terzolo M. *PREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMA*. Endocr Connect. 2018 Sep 1. pii: /journals/ec/aop/ec-18-0400.xml. doi:10.1530/EC-18-0400
28. **Barbot M**, Ceccato F, Lizzul L, Daniele A, Zilio M, Gardiman MP, Denaro L, Emanuelli E, Vianello F, Lombardi G, Rolma G, Scaroni C; Padova Pituitary Club. *Perioperative multidisciplinary management of endoscopic transsphenoidal surgery for sellar lesions: practical suggestions from the Padova model*. Neurosurg Rev. 2019 Jun 22.
29. **Barbot M**, Ceccato F, Scaroni C. *The Pathophysiology and Treatment of Hypertension in Patients with Cushing's Syndrome*. Front Endocrinol (Lausanne). 2019 May 21;10:321.
30. Tedesco S, Adorni MP, Ronda N, Cappellari R, Mioni R, **Barbot M**, Pinelli S, Plebani M, Bolego C, Scaroni C, Bernini F, Fadini GP, Cignarella A. *Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients*. Endocrine. 2019 Apr 16.
31. Armanini D, Bordin L, Donà G, Ceccato F, Barbot M, Scaroni C, Sabbadin C. Pitfalls in urinary sodium excretion. J Clin Hypertens (Greenwich). 2019 Nov;21(11):1635-1636. doi: 10.1111/jch.13702.
32. Tona F, Boscaro M, Barbot M, Maritan L, Famoso G, Dal Lin C, Montisci R, Fallo F, Iliceto S, Scaroni C. New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Microvasc Res. 2020 Mar;128:103940. doi: 10.1016/j.mvr.2019.103940.
33. Caccese M, Barbot M, Ceccato F, Padovan M, Gardiman MP, Fassan M, Denaro L, Emanuelli E, D'Avella D, Scaroni C, Zagonel V, Lombardi G. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs. 2020 Feb;31(2):199-204. doi: 10.1097/CAD.0000000000000856.
34. Regazzo D, Barbot M, Scaroni C, Albiger N, Occhi G. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Rev Endocr Metab Disord. 2020 Mar;21(1):165-183. doi: 10.1007/s11154-019-09536-6.
35. Campello E, Marobin M, Barbot M, Radu CM, Voltan G, Spiezia L, Gavasso S, Ceccato F, Scaroni C, Simioni P. The haemostatic system in acromegaly: a single-centre case-control study. J Endocrinol Invest. 2020 Jan 28. doi:10.1007/s40618-020-01186-9.
36. Ceccato F, Artusi C, Barbot M, Lizzul L, Pinelli S, Costantini G, Niero S, Antonelli G, Plebani M, Scaroni C. Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest. 2020 Feb 14. doi: 10.1007/s40618-020-01197-6.

37. Mariani BMP, Nishi MY, Wanichi IQ, Brondani VB, Lacombe AMF, Charchar H, Pereira MAA, Srougi V, Tanno FY, Ceccato F, Regazzo D, Barbot M, Occhi G, Albiger NME, Vieira-Corrêa M, Kater CE, Scaroni C, Chambô JL, Zerbini MCN, Mendonca BB, Almeida MQ, Fragoso MCBV. Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules. Front Endocrinol (Lausanne). 2020 Feb 7;11:36. doi:10.3389/fendo.2020.00036.
38. Barbot M, Zilio M, Scaroni C. Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. Best Pract Res Clin Endocrinol Metab. 2020 Jan 30:101380. doi: 10.1016/j.beem.2020.101380
39. Ceccato F, Cecchin D, Gregianin M, Ricci G, Campi C, Crimì F, Bergamo M, Versari A, Lacognata C, Rea F, Barbot M, Scaroni C. The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. Endocr Connect. 2020 Mar 1. pii: EC-20-0089.R1. doi: 10.1530/EC-20-0089.
40. Lizzul L, Lombardi G, Barbot M, Ceccato F, Gardiman MP, Regazzo D, Bellu L, Mazza E, Losa M, Scaroni C. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary. 2020 Mar 30. doi: 10.1007/s11102-020-01040-4
41. Barbot M, Ceccato F, Scaroni C. Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing's syndrome. Endocrine. 2020 Aug;69(2):235-236.doi: 10.1007/s12020-020-02390-6.
42. Ceccato F, Lizzul L, Barbot M, Scaroni C. Pituitary-adrenal axis and peripheral cortisol metabolism in obese patients. Endocrine. 2020 Aug;69(2):386-392. doi: 10.1007/s12020-020-02392-4.
43. Barbot M, Regazzo D, Mondin A, Zilio M, Lizzul L, Zaninotto M, Plebani M, Arnaldi G, Ceccato F, Scaroni C. Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary. 2020 Oct;23(5):534-542. doi: 10.1007/s11102-020-01055-x.
44. Ceccato F, Tizianel I, Vedolin CK, Boscaro M, Barbot M, Scaroni C. Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa564. doi: 10.1210/clinem/dgaa564.
45. Ceccato F, Barbot M, Lizzul L, Cuccarollo A, Selmin E, Merante Boschin I, Daniele A, Saller A, Occhi G, Regazzo D, Scaroni C. Clinical presentation and management of acromegaly in elderly patients. Hormones (Athens). 2021 Mar;20(1):143-150. doi: 10.1007/s42000-020-00235-5.
46. Guarnotta V, Ferrigno R, Martino M, Barbot M, Isidori AM, Scaroni C, Ferrante A, Arnaldi G, Pivonello R, Giordano C. Glucocorticoid excess and COVID-19 disease. Rev Endocr Metab Disord. 2021 Dec;22(4):703-714. doi:10.1007/s11154-020-09598-x
47. Beretta F, Dassie F, Parolin M, Boscari F, Barbot M, Busetto L, Mioni R, De Carlo E, Scaroni C, Fallo F, Vettor R, Maffei P. Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. Front Endocrinol (Lausanne). 2020 Sep 11;11:554. doi: 10.3389/fendo.2020.00554.
48. Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, Barbot M, Scaroni C. Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. Int J Mol Sci. 2020 Dec 15;21(24):9554. doi:10.3390/ijms21249554.
49. Torresan F, Crimì F, Ceccato F, Zavan F, Barbot M, Lacognata C, Motta R, Armellin C, Scaroni C, Quaia E, Campi C, Iacobone M. Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. BJS Open. 2021 Jan 8;5(1):zraa061. doi: 10.1093/bjsopen/zraa061
50. Pinelli S, Barbot M, Scaroni C, Ceccato F. Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism. Ann Lab Med. 2021 Nov 1;41(6):521-531. doi: 10.3343/alm.2021.41.6.521.
51. Ceccato F, Barbot M, Scaroni C, Boscaro M. Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. J Endocrinol Invest. 2021 Dec;44(12):2749-2763. doi: 10.1007/s40618-021-01615-3.
52. Ceccato F, Lizzul L, Voltan G, Barbot M, Scaroni C. Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Pituitary. 2021 Dec;24(6):914-921. doi:10.1007/s11102-021-01165-0.
53. Ceccato F, Selmin E, Antonelli G, Barbot M, Daniele A, Boscaro M, Plebani M, Scaroni C. Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. Endocr Connect. 2021 Sep 20;10(9):1189-1199. doi: 10.1530/EC-21-0404.
54. Chasseloup F, Bourdeau I, Tabarin A, Regazzo D, Dumontet C, Ladurelle N, Tosca L, Amazit L, Proust A, Scharfmann R, Mignot T, Fiore F, Tsagarakis S, Vassiliadi D, Maiter D, Young J, Lecoq AL, Deméocq V, Salenave S, Lefebvre H, Cloix L, Emy P, Dessailloud R, Vezzosi D, Scaroni C, Barbot M, de Herder W, Pattou F, Tétreault M, Corbeil G, Dupeux M, Lambert B, Tachdjian G, Guiochon-Mantel A, Beau I, Chanson P, Viengchareun S, Lacroix A, Bouligand J, Kamenický P. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol. 2021 Dec;9(12):813-824. doi:10.1016/S2213-8587(21)00236-9.

55. Ferrante E, Barbot M, Serban AL, Ceccato F, Carosi G, Lizzul L, Sala E, Daniele A, Indirli R, Cuman M, Locatelli M, Manara R, Arosio M, Boscaro M, Mantovani G, Scaroni C. Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. J Endocrinol Invest. 2022 Mar;45(3):629-637. doi: 10.1007/s40618-021-01695-1.
56. Sabbadin C, Beggiao F, Keiko Vedolin C, Orlando G, Ragazzi E, Ceccato F, Barbot M, Bordin L, Donà G, Andrisani A, Belloni Fortina A, Scaroni C, Armanini D. Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. Endocr Metab Immune Disord Drug Targets. 2023;23(2):188-195. doi: 10.2174/1871530322666220509051746.
57. Barbot M, Mondin A, Regazzo D, Guarnotta V, Basso D, Giordano C, Scaroni C, Ceccato F. Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy. Int J Mol Sci. 2022 May 6;23(9):5217. doi:10.3390/ijms23095217.
58. Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. Int J Mol Sci. 2022 Jun 9;23(12):6469. doi: 10.3390/ijms23126469.
59. Mondin A, Manara R, Voltan G, Tizianel I, Denaro L, Ferrari M, Barbot M, Scaroni C, Ceccato F. Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2022 Jul 1;13:935759. doi: 10.3389/fendo.2022.935759.
60. Ceccato F, Torchio M, Tizianel I, Peleg Falb M, Barbot M, Sabbadin C, Betterle C, Scaroni C. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency. J Endocrinol Invest. 2023 Jan;46(1):111-122. doi: 10.1007/s40618-022-01889-1.
61. Sabbadin C, Falb MP, Voltan G, Tizianel I, Padoan A, Betterle C, Basso D, Plebani M, Barbot M, Scaroni C, Ceccato F. Serological Evidence and Self-reported Outcomes in Patients with Adrenal Insufficiency during the First Waves of COVID-19 in North-East Italy. Endocr Metab Immune Disord Drug Targets. 2024;24(14):1677-1685. doi: 10.2174/1871530322666220811103755.
62. Barbot M, Mazzeo P, Lazzara M, Ceccato F, Scaroni C. Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol (Lausanne). 2022 Aug 1;13:934675. doi: 10.3389/fendo.2022.934675.
63. Iraqi HM, Pigarova E, Zacharieva S, Colao A, Baraf L, Tsoli M, Doknic M, Bitti SR, Giordano R, Barbot M, Akirov A, Witek P, Serebro M, Auer MK, Tóth M, Shimon I. Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study. Pituitary. 2022 Dec;25(6):982-987. doi: 10.1007/s11102-022-01277-1.
64. Ceccato F, Barbot M, Mondin A, Boscaro M, Fleseriu M, Scaroni C. Dynamic Testing for Differential Diagnosis of ACTH-Dependent Cushing Syndrome: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023 Apr 13;108(5):e178-e188. doi: 10.1210/clinem/dgac686.
65. Ceccato F, Vedolin CK, Voltan G, Antonelli G, Barbot M, Basso D, Regazzo D, Scaroni C, Occhi G. Paradoxical GH increase after oral glucose load in subjects with and without acromegaly. J Endocrinol Invest. 2024 Jan;47(1):213-221. doi:10.1007/s40618-023-02138-9.
66. Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, Denaro L, Scaroni C, Barbot M. Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre. Pituitary. 2023 Oct;26(5):551-560. doi: 10.1007/s11102-023-01343-2.
67. Piva I, Censi S, Manso J, Barollo S, Bertazza L, Scaroni C, Mian C, Barbot M. A Novel TSH Receptor Gene Variant Associated with Non-Autoimmune Hyperthyrotropinemia: A Case Report. Endocr Metab Immune Disord Drug Targets.2024;24(2):273-276.
68. Voltan G, Antonelli G, Mondin A, Tizianel I, Sabbadin C, Barbot M, Basso D, Scaroni C, Ceccato F. Heat inactivation of SARS-CoV 2 enabled the measurement of salivary cortisol during COVID-19 pandemic. Endocrine. 2024 Mar;83(3):775-782. doi: 10.1007/s12020-023-03597-z
69. Pollis RM, Furlanetto D, Pagin E, Scaroni C, Barbot M, Voltan G. Ketosis-prone Diabetes Presenting with Acute Esophageal Necrosis or "Black Esophagus": An Intriguing New Clinical Association. Endocr Metab Immune Disord Drug Targets. 2024;24(7):857-863. doi: 10.2174/0118715303279019231127065331
70. Regazzo D, Avallone S, MacSweeney CP, Sergeev E, Howe D, Godwood A, Bennett KA, Brown AJH, Barnes M, Occhi G, Barbot M, Faggian D, Tropeano MP, Losa M, Lasio G, Scaroni C, Pecori Giraldi F. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas. Eur J Endocrinol. 2024 Jan 3;190(1):K8-K16. doi: 10.1093/ejendo/lvad171.

71. Mazzeo P, Ceccato F, Manara R, Mazzon C, Barbot M. Transient Central Diabetes Insipidus (Arginine Vasopressin Deficiency) Following SARS-CoV-2 Vaccination: A Case Report and Literature Review. Endocr Metab Immune Disord Drug Targets. 2024;24(15):1856-1864. doi: 10.2174/0118715303286560231124115052
72. Bavaresco A, Mazzeo P, Lazzara M, Barbot M. Adipose tissue in cortisol excess: What Cushing's syndrome can teach us? Biochem Pharmacol. 2024 May;223:116137. doi: 10.1016/j.bcp.2024.116137
73. Tizianel I, Barbot M, Ceccato F. Subtyping of Cushing's Syndrome: A Step Ahead. Exp Clin Endocrinol Diabetes. 2024 Dec;132(12):659-669. doi:10.1055/a-2299-5065
74. Mazzeo P, Tizianel I, Galuppini F, Sbaraglia M, Barbot M. Uncommon adrenal rest tumors and massive adrenal enlargement in adult with congenital adrenal hyperplasia mimicking metastasis from pleomorphic sarcoma. BMC Endocr Disord. 2024 Jul 8;24(1):103. doi: 10.1186/s12902-024-01635-z.
75. Sabbadin C, Graziani A, Bavaresco A, Mazzeo P, Tizianel I, Ceccato F, Armanini D, Barbot M. Pseudohyperaldosteronism Due to Licorice: A Practice-Based Learning from a Case Series. Int J Mol Sci. 2024 Jul 7;25(13):7454. doi:10.3390/ijms25137454.
76. Ceccato F, Bavaresco A, Ragazzi E, Barbot M, Boscaro M, Basso D, Scaroni C, Antonelli G. Clinical and Biochemical Data for the Diagnosis of Endogenous Hypercortisolism: The "Cushingomic" Approach. J Clin Endocrinol Metab. 2025 Jan 21;110(2):396-405. doi: 10.1210/clinem/dgae517.
77. Mondin A, Ceccato F, Scaroni C, Barbot M. Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing's Disease. Endocr Metab Immune Disord Drug Targets. 2025;25(10):824-833. doi: 10.2174/0118715303328077240719055819.
78. Barbot M, Lazzara M, Mazzeo P, Pecori Giraldi F. Correction: Unusual infections and thrombotic events in Cushing's syndrome. J Endocrinol Invest. 2025 Apr;48(Suppl 1):45. doi: 10.1007/s40618-024-02486-0. Erratum for: J Endocrinol Invest. 2025 Apr;48(Suppl 1):35-43. doi: 10.1007/s40618-024-02454-8.
79. Voltan G, Mazzeo P, Cannito M, Pinelli S, Barbot M, Scaroni C, Ceccato F, Camozzi V. Relationship Among Fragility Fractures and the Overall Cardiovascular Burden in Endogenous Cushing Syndrome. J Endocr Soc. 2025 Jan 17;9(3):bvaf008. doi: 10.1210/jendso/bvaf008.
80. Tizianel I, Madinelli A, Crimì F, Barbot M, Censi S, Sabbadin C, Ceccato F. Prevalence of Metabolic-Associated Steatotic Liver Disease in Patients With Primary Aldosteronism. Clin Endocrinol (Oxf). 2025 Jun;102(6):618-625. doi:10.1111/cen.15231
81. Tizianel I, Lizzul L, Mondin A, Voltan G, Mazzeo P, Scaroni C, Barbot M, Ceccato F. Cardiometabolic complications after Cushing's disease remission. J Endocrinol Invest. 2025 Jul;48(7):1597-1610. doi: 10.1007/s40618-025-02572-x.
82. Mazzeo P, Ceccato F, Tizianel I, Barbot M. A Challenging Case of Congenital Adrenal Hyperplasia Due to CYP11B1 Deficiency With Uncontrolled Hypertension. Case Rep Endocrinol. 2025 Apr 11;2025:1422782. doi: 10.1155/crie/1422782
83. Mondin A, Bovo G, Antonelli G, Faggian D, Mazzeo P, Bavaresco A, Ceccato F, Barbot M. Enhancing diagnostic tools for vasopressin deficiency: insights from a single-center cohort study. Pituitary. 2025 May 29;28(3):65. doi:10.1007/s11102-025-01538-9
84. Mondin A, Bovo G, Barbot M, Fleseriu M, Denaro L, Scaroni C, Ceccato F. PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study. Endocrine. 2025 Sep;89(3):834-845. doi:10.1007/s12020-025-04292-x.
85. Mazzeo P, Tizianel I, Sabbadin C, Voltan G, Antonelli G, Ceccato F, Barbot M. Impact of dual-release hydrocortisone on disease control and metabolism in congenital adrenal hyperplasia: a retrospective cohort study. Endocrine. 2025 Oct;90(1):329-338. doi: 10.1007/s12020-025-04328-2

Indici bibliometrici

- H-index: 27 (scopus)
- Total citations: 1992 (scopus)

Affiliazioni a società:

Membro di: Società Italiana di Endocrinologia (SIE), Società Spagnola di Endocrinologia e Nutrizione (SEEN), European Society of Endocrinology (ESE) and European Association of Neuroendocrinology (ENEA)
Ex socio e membro del comitato scientifico della SIA dal 2016-2018.

Attività di revisore per:

Editore sezione Adrenal per: Frontiers Endocrinology
European Journal of endocrinology, Journal of Endocrinological Investigation, Endocrinology, Endocrine, Pituitary, Diabetes & Metabolism Case Reports, Endocrine Connections, BioFactors, BMC Endocrine disorders

Attività didattica

Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo
CdL Dietistica
CdL Medicine and Surgery
CdL Ortottica e assistenza oftalmologica
CdL Fisioterapia

Trials clinici:

- **NBI-74788-CAH3003:** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
- **CSOM230B2411:** A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease. Sponsor: Novartis.
- **CSOM230G2304:** A randomized, double blind, multicenter, phase III trial study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing's Disease. Sponsor: Novartis.
- **PROMPT:** Prospective, single arm, open-label, multicenter, international study to assess the effects of mtyrapone in patients with endogenous Cushing's syndrome during a 12-week treatment period followed by an extension period of 24 weeks.
- **METYX01:** A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing's syndrome due to adrenal adenoma
- **RECAP:** Studio osservazione retrospettivo monocentrico per la valutazione del trattamento corrente dell'insufficienza surrenalica attraverso la revisione delle cartelle cliniche dei pazienti. Sponsor: Shire/ViroPharma
- **CLCI699C2301**: Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease
- **CSOM230B2410:** A Phase IV trial. Sponsor: Novartis.

Premi:

Premio poster (39° Congresso Nazionale SIE, Roma, 21-24 Giugno 2017)

Premio presentazione orale CEUM Young Edition 2018, 5-6 Luglio 2018

Premio Mario e Lina Austoni (UNIPD)

Progetti di ricerca:

Respondabile locale di progetto: Bando Ricerca Finalizzata 2018 giovani ricercatori (responsabile dott Guido di Dalmazi): "Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome"
Responsabile locale di progetto PRIN:

© European Union, 2002-2013 | http://europass.cedefop.europa.eu

Relatore di tesi di laurea corso di laurea in Medicina e Chirurgia

Anno accademico 2022-2023: “Efficacia e sicurezza della terapia con somatotropina umana ricombinante in pazienti adulti affetti da deficit di GH”

Anno accademico 2022-2023: “Iperplasia surrenalica congenita: rischio cardiovascolare associato alla terapia cronica cortisonica”

Anno accademico 2023-2024: “Studio morfologico e funzionale tiroideo nei pazienti con sindrome di Cushing”

Anno accademico 2024-2025: “Impact of Modified-Release Hydrocortisone on circadian cortisol rhythms and disease control in Congenital Adrenal Hyperplasia”

Correlatore di tesi di laurea corso di laurea in Medicina e Chirurgia:

Anno accademico 2014-2015: “Ritmo del cortisolo salivare valutato con LC-MS/MS: nuova indagine nello studio degli incidentalomi surrenalici”

Anno accademico 2015-2016: “Adenoma ipofisario ACTH-secernente: confronto tra micro- e macro-adenoma”

Anno accademico 2017-2018: “Predittori clinici e biochimici dello sviluppo di diabete in corso di terapia con pasireotide nella malattia di Cushing”

Anno accademico 2017-2018: “Ruolo dei test di secondo livello nella diagnosi di sede della sindrome di Cushing ACTH-dipendente”

Anno accademico 2018-2019: “Risultati della chirurgia endoscopica transnasosfenoidale nella malattia di Cushing: outcome e complicanze nella casistica padovana”

Anno accademico 2018-2019: “Qualità di vita e complicanze a lungo termine dell'eccesso di glucocorticoidi nei pazienti con sindrome di Cushing: confronto tra diversi approcci terapeutici”

Anno accademico 2018-2019: “Rischio cardiovascolare e metabolico in pazienti adulti con iperplasia surrenalica congenita”

Padova, 31/12/2025

Dott Mattia Barbot

© European Union, 2002-2013 | http://europass.cedefop.europa.eu